Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifinatamab deruxtecan in pretreated ES-SCLC
NCT05280470Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2022
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of ifinatamab deruxtecan in small cell lung cancer (SCLC), sponsored by Daiichi Sankyo Co., Ltd.. Started Mar 2022; status: active, not recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05280470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05280470.